Skip to main content
. 2022 Jan 12;14(1):176. doi: 10.3390/pharmaceutics14010176

Figure 1.

Figure 1

Study overview. A schematic of our anti-SARS-CoV-2 compound screening process. The anti-SARS-CoV-2 potential of 12 compounds was first analyzed through molecular docking using DockCoV2. Next, the inhibitory effect of those compounds on TMPRSS2, 3CLpro, and PLpro was tested. The RBD attachment assay indicated the ability of the compound to block the interaction between the spike RBD and ACE2. Finally, the plaque reduction assay revealed the antiviral activity of the compounds.